Use of Padua and Caprini Risk Assessment Models for VTE Prophylaxis
Use the Padua Prediction Score (≥4 points = high risk) for hospitalized medical patients and the Caprini score (≥5 points = high risk for surgical patients; specific thresholds vary) for surgical patients to determine who needs pharmacologic VTE prophylaxis. For high-risk patients identified by either model, initiate LMWH (enoxaparin 40 mg subcutaneously once daily or dalteparin 5,000 units subcutaneously once daily) or fondaparinux 2.5 mg subcutaneously once daily, continuing throughout hospitalization for medical patients and for at least 7-10 days (up to 4 weeks for high-risk cases) in surgical patients 1.
Risk Stratification Framework
For Medical Inpatients: Padua Prediction Score
The Padua score stratifies medical patients into low risk (0-3 points) versus high risk (≥4 points) 2. High-risk patients (Padua ≥4) have an 11% VTE incidence without prophylaxis compared to 0.3% in low-risk patients, with prophylaxis reducing this to 2.2% 2.
Padua score components (score ≥4 indicates high VTE risk):
- Active cancer: 3 points
- Previous VTE: 3 points
- Reduced mobility: 3 points
- Known thrombophilic condition: 3 points
- Recent trauma/surgery (<1 month): 2 points
- Age >70 years: 1 point
- Heart/respiratory failure: 1 point
- Acute MI or ischemic stroke: 1 point
- Acute infection or rheumatologic disorder: 1 point
- Obesity (BMI >30): 1 point
- Ongoing hormonal treatment: 1 point 2
For Surgical Patients: Caprini Score
The Caprini score stratifies surgical patients into four risk categories:
- Very low risk: 0 points (0.5% VTE risk)
- Low risk: 1-2 points (1.5% VTE risk)
- Moderate risk: 3-4 points (3% VTE risk)
- High risk: ≥5 points (6% VTE risk) 1
Critical threshold for extremely high-risk patients: Caprini score ≥11 identifies patients with 59% DVT incidence despite standard prophylaxis, compared to only 3% in those with scores <11 3. These patients may require intensified prophylaxis regimens beyond standard dosing.
Anticoagulant Regimens Based on Risk Scores
High-Risk Medical Patients (Padua ≥4)
- Enoxaparin: 40 mg subcutaneously once daily
- Dalteparin: 5,000 units subcutaneously once daily
- Fondaparinux: 2.5 mg subcutaneously once daily (reduce to 1.5 mg if CrCl 30-50 mL/min)
- Unfractionated heparin: 5,000 units subcutaneously every 8 hours (particularly for cancer patients)
Duration: Continue throughout hospitalization or until fully ambulatory 1.
High-Risk Surgical Patients (Caprini ≥5)
Perioperative regimens 1:
Enoxaparin:
- 40 mg subcutaneously 2-4 hours preoperatively OR 10-12 hours preoperatively
- Continue 40 mg once daily postoperatively
- Duration: 10-14 days minimum; extend to 4 weeks for cancer patients or major abdominal/pelvic surgery 1
Dalteparin:
- Low risk: 2,500 units once daily
- High risk: 2,500 units 2-4 hours preoperatively, then 5,000 units once daily
- Duration: 10-14 days minimum; consider up to 35 days 1
Fondaparinux:
- 2.5 mg subcutaneously once daily beginning 6-8 hours postoperatively
- Duration: 10-14 days; consider up to 35 days 1
Unfractionated heparin:
- 5,000 units 2-4 hours preoperatively and every 8 hours thereafter
- Duration: 10-14 days; consider up to 35 days 1
Cancer Patients: Special Considerations
All hospitalized cancer patients with active malignancy and additional risk factors should receive pharmacologic thromboprophylaxis 4, 5. For surgical cancer patients, extend prophylaxis to 4 weeks with LMWH 1. Unfractionated heparin dosing for cancer patients is 5,000 units every 8 hours (not every 12 hours, which is less effective) 4, 6.
For outpatient cancer patients receiving chemotherapy:
- Pancreatic cancer: LMWH or DOACs (rivaroxaban/apixaban) recommended 7
- Khorana score ≥2: Consider rivaroxaban or apixaban 7
- Myeloma with immunomodulatory drugs: LMWH, low-dose aspirin, or apixaban 7
Comparative Performance and Clinical Nuances
The Caprini score demonstrates higher sensitivity (96%) than Padua (64.3%) but was originally designed for surgical patients 8. In medical inpatients, the Caprini RAM can identify 84.3% of VTE cases who would benefit from prophylaxis, whereas Padua identifies only 49.1% 9. However, recent large-scale data from 1.25 million Veterans Affairs patients showed both models have limited predictive ability (AUCs 0.56-0.59) in unselected general hospital populations 10, suggesting these tools work best in higher-risk cohorts.
Critical discordance issue: In surgical patients, approximately 40% with high Caprini scores (≥5) have discordant low Padua scores (<4) 11. This suggests the Caprini score is more appropriate for surgical patients, while Padua should be reserved for medical patients 11, 9.
Mechanical Prophylaxis
For patients with contraindications to pharmacologic prophylaxis (active bleeding, severe thrombocytopenia, recent neurosurgery), use mechanical methods:
- Graduated compression stockings (18-21 mm Hg)
- Intermittent pneumatic compression
- Continue until bleeding risk diminishes, then add pharmacologic prophylaxis 1
Important caveat: Mechanical prophylaxis alone is not recommended as monotherapy except when pharmacologic methods are absolutely contraindicated 7.
Common Pitfalls to Avoid
Do not use the Padua score for surgical patients—it will underestimate risk in approximately 40% of high-risk surgical cases 11
Do not stop prophylaxis at hospital discharge for high-risk patients—extend to 4 weeks for major abdominal/pelvic surgery, cancer patients, or Caprini scores ≥11 1, 3
Adjust LMWH dosing for renal impairment—avoid enoxaparin/dalteparin/tinzaparin if CrCl <30 mL/min or use anti-Xa monitoring 5
For Caprini scores ≥11, standard prophylaxis may be insufficient—these extremely high-risk patients (59% DVT rate) may require intensified regimens or extended duration 3
Do not use rivaroxaban for routine medical inpatient prophylaxis—the MAGELLAN trial showed increased bleeding without clear net benefit 1